The company under discussion recently secured funding on February 22, 2022, and has obtained three grants totaling 15,000€ from European sources. Their social media presence includes over 1,350 followers on one platform and 900 followers combined across two other accounts, along with noticeable engagement on LinkedIn, a moderately trafficked website, and a modest following on other platforms such as TikTok, YouTube, and Discord. The company also utilizes polls, official testimonials, and advisory networks. It gains traction through a robust incubator list with access to over 4,850 recurring opportunities and a venture capital archive of more than 30,000 angel investors and 15,000 venture capitalists. A detailed blog focuses on tDCS, supported by a unique video series. Clinical trials have been conducted, involving 12 patients over 8 weeks, with patent preparations underway. The product, a unique tDCS model, and its designs are finalized, with several alternative versions available. The organization collaborates with numerous accelerators and partners in its endeavors. These collaborations enhance their research and development capabilities, as well as clinical trial operations. Sales partnerships exist with several exclusive partners, allowing for broader distribution channels. The company seeks investment for an upcoming seminar and targets various client demographics: students managing ADHD, individuals dealing with depression, business professionals overcoming addictions, and adults addressing cognitive decline. These demographics range in age and focus on improving various aspects of mental health and performance.